Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-30T06:35:02.590Z Has data issue: false hasContentIssue false

1673 – Evaluation Of Sleep And Pain In Newly Diagnosed Patients With Generalised Anxiety Disorder (gad): The Espiga Study

Published online by Cambridge University Press:  15 April 2020

C. Allgulander
Affiliation:
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
D.S. Baldwin
Affiliation:
Department of Psychiatry, University of Southampton, Southampton, UK
C. Gastó
Affiliation:
Institut de Neurociències, Hospital Clinic Barcelona, Barcelona, Spain
S. Pirkola
Affiliation:
Department of Psychiatry, University of Oulu, Lapland Hospital District, Oulu, Finland
H.-U. Wittchen
Affiliation:
Institute of Clinical Psychology and Psychotherapy, Technische Universitaet Dresden, Dresden, Germany
G. Atkinson
Affiliation:
Primary Care Business Unit
H. Haswell
Affiliation:
EU Medical Department, Pfizer Ltd., Tadworth, UK
R. Prieto
Affiliation:
EU Medical Department, Pfizer, SLU, Alcobendas (Madrid), Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

In the general population the 12-month prevalence of GAD is estimated to be about 2%. Higher prevalences have been found in primary care settings, with estimates of well over 6%. The role of sleep problems and pain in GAD remains understudied.

Objectives

To evaluate the frequency of sleep problems and pain in newly diagnosed GAD patients in 5 European countries.

Methods

Non-interventional, cross-sectional survey of 1650 adult patients newly diagnosed with GAD in primary care settings. Assessment included clinical interview rating and self report data.

Results

Mean age of the sample was 49.2 years (SD; 14.5). Mean GAD-7 score was 14.8 (SD; 3.1) and the median duration of symptoms was 12.0 months. The proportion with sleep disturbance and pain were 85.9% and 75.9%, respectively. Disturbed sleep had persisted for a median of 9.0 months and was mainly classified as “difficulty in falling asleep” (76.1%) or “nocturnal awakening” (58.8%). The median duration of pain was 6.0 months, and located mainly in the cervical region (47.0%) and upper back/limbs (40.1%). The mean number of days that patients were unable to work because of GAD-related health problems during the preceding 3 month period was 10.8 (95%CI; 9.6-12.0). The proportion of patients that visited the primary care physician and specialist during the preceding 3 months was 93.8% and 40.3%, respectively.

Conclusions

Sleep problems and pain are extremely frequent characteristics of GAD, contributing to the disability and work productivity profile associated with GAD as well as the patients’ use of health care resources.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.